Baxter International Inc. has announced pivotal Phase III study results evaluating the efficacy and safety of routine prophylaxis compared to...
An investigator-initiated study (Pro-FEIBA) evaluated the prophylactic use of FEIBA [Anti-inhibitor Coagulant Complex] from Baxter, to ascertain if it can...
Baxter International Inc. announced that the FDA granted approval on 19 December 2013 of Baxter's FEIBA [ Anti-Inhibitor Coagulant Complex...
• Treatment of spontaneous bleeding and cover of surgical interventions in haemophilia A patients with Factor VIII inhibitors • Treatment of spontaneous bleeding and cover of surgical interventions in non haemophiliacs with acquired inhibitors to Factor VIII • Prophylaxis in haemophilia A patients with high-responding inhibitors and frequent joint bleeding
Shire plc will present an update on its safety database describing 40 years of real-world experience with the bypassing agent...
Baxalta, spun out of Baxter, launches on 1 July 2015 to develop and promote products in haematology, immunology and to...
The CHMP recommends marketing authorisation for recombinant porcine Factor VIII Obizur (susoctocog alfa) from Baxalta for treatment of acquired haemophilia...
Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge.